Technical Analysis for MPH - Medicure Inc.

Grade Last Price % Change Price Change
D 1.080 0.00% 0.000
MPH closed up 8.0 percent on Wednesday, July 24, 2024, on 2.95 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish 8.00%
Calm After Storm Range Contraction 8.00%
Narrow Range Bar Range Contraction 8.00%
Fell Below 20 DMA Bearish 8.00%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High 11 days ago
Rose Above Upper Bollinger Band 11 days ago
Up 1 ATR 11 days ago
Up 5% 11 days ago
Up 3% 11 days ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Medicure Inc. Description

Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Chemistry Marketing Medicine Pharma Pharmaceutical Clinic Drug Skin Organ Systems Pharmaceutical Industry Biopharmaceutical Disorders Cardiology Neurological Disorders

Is MPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.8
52 Week Low 0.92
Average Volume 5,115
200-Day Moving Average 1.298
50-Day Moving Average 1.088
20-Day Moving Average 1.097
10-Day Moving Average 1.113
Average True Range 0.068
RSI (14) 48.72
ADX 14.21
+DI 40.186
-DI 38.739
Chandelier Exit (Long, 3 ATRs) 1.047
Chandelier Exit (Short, 3 ATRs) 1.203
Upper Bollinger Bands 1.231
Lower Bollinger Band 0.963
Percent B (%b) 0.44
BandWidth 24.467
MACD Line 0.000
MACD Signal Line 0.005
MACD Histogram -0.0051
Fundamentals Value
Market Cap 11.29 Million
Num Shares 10.5 Million
EPS -0.18
Price-to-Earnings (P/E) Ratio -6.14
Price-to-Sales 0.79
Price-to-Book 0.32
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.200
Resistance 3 (R3) 1.210 1.180 1.180
Resistance 2 (R2) 1.180 1.149 1.175 1.173
Resistance 1 (R1) 1.130 1.131 1.115 1.120 1.167
Pivot Point 1.100 1.100 1.093 1.095 1.100
Support 1 (S1) 1.050 1.069 1.035 1.040 0.993
Support 2 (S2) 1.020 1.051 1.015 0.987
Support 3 (S3) 0.970 1.020 0.980
Support 4 (S4) 0.960